Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

No significant associations were observed for insufficient 25(OH)D or for concentrations measured at 8 weeks’ gestation.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A secondary analysis of the EAGeR Trial (2006 to 2012), which was a multisite, prospective, double-blind, block-randomized, placebo-controlled clinical trial of women with regular menstrual cycles and 1 to 2 prior pregnancy losses.

Source: Abstract.

This study was a secondary analysis from the Effects of Aspirin in Gestation and Reproduction (EAGeR) trial, which was a multisite, prospective, double-blind, block-randomized, placebo-controlled clinical trial designed to evaluate the effect of low-dose aspirin (LDA) on live births in 1,228 healthy women with regular menstrual cycles and 1 to 2 prior pregnancy losses.[] Women between 18 and 40 years of age were enrolled in the trial and were followed up to 6 months while trying to conceive and throughout pregnancy if they conceived, of which 597 had a live birth ().

Source: Methods.

Women were excluded from the trial if they had any chronic use of anti-inflammatory drugs, major medical disorders (e.g., diabetes), or any prior diagnoses of infertility (e.g., polycystic ovarian syndrome, endometriosis).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Preconception vitamin D status and subsequent risk of preeclampsia: A secondary cohort analysis from the EAGeR trial

Secondary analysis · Pregnancy hypertension · 2026

Original publication title

Preconception vitamin D status and subsequent risk of preeclampsia: A secondary cohort analysis from the EAGeR trial

Zeina M. Alkhalaf; Sunni L. Mumford; Edmond D. Shenassa; Enrique F. Schisterman; Robert M. Silver; Marie E. Thoma

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Deficient preconception 25(OH)D levels may be associated with an increased risk of preeclampsia, although this relationship appears partly mediated by BMI. These findings highlight the preconception period as a potentially critical window for optimizing maternal vitamin D status and reducing future preeclampsia risk. Addressing maternal nutritional status before conception may offer a novel prevention strategy warranting confirmation in larger and more diverse populations.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To evaluate associations between maternal serum 25-hyroxyvitamin D [25(OH)D] measured at both preconception and 8 weeks gestation and the risk of preeclampsia.

Source: Objective:

Abstract: Study design

A secondary analysis of the EAGeR Trial (2006 to 2012), which was a multisite, prospective, double-blind, block-randomized, placebo-controlled clinical trial of women with regular menstrual cycles and 1 to 2 prior pregnancy losses. Analyses were restricted to participants who conceived and had a live birth (N = 552) and serum 25(OH)D measured at preconception and 8 weeks’ gestation.

Source: Study design:

Abstract: Main outcome measures

Log-binomial regression with robust standard errors estimated risk ratios (RR) and 95% confidence intervals (CI) for preeclampsia across 25(OH)D categories. Inverse probability weighting accounted for selection bias from restricting analyses to live births.

Source: Main outcome measures:

Abstract: Results

Overall, 55 (10.0%) women developed preeclampsia. In adjusted models excluding body mass index (BMI), deficient preconception 25(OH)D levels (≤20 ng/ml) were associated with an increased preeclampsia risk (RR: 2.32, 95% CI: 1.09, 4.95) compared with sufficient levels (≥30 ng/ml). These associations were attenuated after adjusting for BMI and other covariates (RR: 1.45, 95% CI: 0.64, 3.29). No significant associations were observed for insufficient 25(OH)D or for concentrations measured at 8 weeks’ gestation.

Source: Results:

Abstract: Conclusion

Deficient preconception 25(OH)D levels may be associated with an increased risk of preeclampsia, although this relationship appears partly mediated by BMI. These findings highlight the preconception period as a potentially critical window for optimizing maternal vitamin D status and reducing future preeclampsia risk. Addressing maternal nutritional status before conception may offer a novel prevention strategy warranting confirmation in larger and more diverse populations.

Source: Conclusion:
Authors’ abstract

Objective:

To evaluate associations between maternal serum 25-hyroxyvitamin D [25(OH)D] measured at both preconception and 8 weeks gestation and the risk of preeclampsia.

Study design:

A secondary analysis of the EAGeR Trial (2006 to 2012), which was a multisite, prospective, double-blind, block-randomized, placebo-controlled clinical trial of women with regular menstrual cycles and 1 to 2 prior pregnancy losses. Analyses were restricted to participants who conceived and had a live birth (N = 552) and serum 25(OH)D measured at preconception and 8 weeks’ gestation.

Main outcome measures:

Log-binomial regression with robust standard errors estimated risk ratios (RR) and 95% confidence intervals (CI) for preeclampsia across 25(OH)D categories. Inverse probability weighting accounted for selection bias from restricting analyses to live births.

Results:

Overall, 55 (10.0%) women developed preeclampsia. In adjusted models excluding body mass index (BMI), deficient preconception 25(OH)D levels (≤20 ng/ml) were associated with an increased preeclampsia risk (RR: 2.32, 95% CI: 1.09, 4.95) compared with sufficient levels (≥30 ng/ml). These associations were attenuated after adjusting for BMI and other covariates (RR: 1.45, 95% CI: 0.64, 3.29). No significant associations were observed for insufficient 25(OH)D or for concentrations measured at 8 weeks’ gestation.

Conclusion:

Deficient preconception 25(OH)D levels may be associated with an increased risk of preeclampsia, although this relationship appears partly mediated by BMI. These findings highlight the preconception period as a potentially critical window for optimizing maternal vitamin D status and reducing future preeclampsia risk. Addressing maternal nutritional status before conception may offer a novel prevention strategy warranting confirmation in larger and more diverse populations.

Publication and source details

Original title: Preconception vitamin D status and subsequent risk of preeclampsia: A secondary cohort analysis from the EAGeR trial

Zeina M. Alkhalaf; Sunni L. Mumford; Edmond D. Shenassa; Enrique F. Schisterman; Robert M. Silver; Marie E. Thoma

Pregnancy hypertension · 2026

* Corresponding author at: 4200 Valley Drive, College Park, MD 20742 (703) 625-9470, USA. zalkhala@umd.edu (Z.M. Alkhalaf).https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:06:22.086691+00:00

DOI: 10.1016/j.preghy.2026.101417 · PMC13361926